BioNTech Expands its 2020 Collaboration with Regeneron to Advance FixVac and Libtayo (cemiplimab) for the Treatment of NSCLC
Shots:
- The companies plan to jointly conduct the clinical trials to evaluate FixVac + Libtayo in different patient populations with NSCLC & will equally share the development costs for the clinical trials
- The agreement follows the Aug 2020 collaboration of the combination of BioNTech’s FixVac BNT111 + Libtayo for advanced melanoma. Following a separate agreement, BioNTech will be responsible to conduct & sponsor a P-I (LuCa-MERIT-1) trial for the combination in subpopulations with NSCLC
- BNT111 has received the US FDA’s Fast Track Designation and is being evaluated in a randomized P-II trial. The therapy is also being studied in a P-I trial in combination with Libtayo for prostate cancer
Ref: Globe Newswire | Image: BionTech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
